FDA Grants ‘Priority Review’ Of Plant-Derived CBD Extract

If Epidiolex achieves FDA-approval, analysts suggest the product could retail for between $30,000 to $60,000 annually.

DISTRICT OF COLUMBIA: Representatives of the US Food and Drug Administration will undertake a ‘priority review‘ of data specific to the safety and efficacy of Epidiolex, a standardized, plant-derived CBD extract formulated by a British pharmaceutical company. The review is scheduled to be completed by June 27, 2018. Phase III clinical trial data shows that Epidiolex Read the full article…

MMJ International Holdings Pursuing Legal FDA Cannabis Medicine Approval

MMJ International Holdings Pursuing Legal FDA Cannabis Medicine Approval

NEW YORK: MMJ International Holdings announced that its affiliate, MMJ Bioscience, has finalized a partnership agreement with Terra Life Science group, a private Canadian based pharmaceutical manufacturer, to produce cannabis medicines for the groups FDA approved studies. Last weeks announcement by Attorney General Sessions on the recision of the Cole Memorandum positions MMJ International Holdings as Read the full article…

World Health Organization: CBD Should Not Be Subject To International Drug Controls

hemp CBD oil

SWITZERLAND: Use of the naturally occurring cannabinoid CBD (cannabidiol) possesses no likely abuse potential and should not be subject to international drug scheduling restrictions, according to recommendations issued this week by the World Health Organization’s (WHO) Expert Committee on Drug Dependence. Stated WHO: “Recent evidence from animal and human studies shows that its use could have some therapeutic value for seizures due Read the full article…

iCan Israel-Cannabis To Bring FDA Approved Nebulizers To Medical Cannabis Market

The Nebican Portable Nebulizer for Medical Cannabis delivery

ISRAEL: iCAN Israel-Cannabis and Aura Medical have joined forces to bring FDA approved nebulizers to the burgeoning medical cannabis market. The Aura’s Portable Nebulizer is widely acclaimed and recommended by the nation’s top Pulmonologists and Respiratory Therapists for use in treating asthma and COPD and now will be used by millions more worldwide. The device will Read the full article…

FDA Wants To Hear Your Thoughts About CBD

MMJ International Holdings Pursuing Legal FDA Cannabis Medicine Approval

DISTRICT OF COLUMBIA: The US Food and Drug Administration is soliciting public comments with regard to the therapeutic utility and abuse liability of various substances, including cannabidiol (CBD). The agency will consider these comments prior to preparing a formal response to the World Health Organization, which is considering placing the substances within their international drug scheduling code. Cannabidiol is defined by the Read the full article…

DEA To Classify Liquid, Synthetic THC As A Schedule II Controlled Substance

DEA to classify liquid THC

DISTRICT OF COLUMBIA: Officials from the US Drug Enforcement Administration (DEA) have recommended that Syndros, a liquid form of synthetic THC, be classified as a Schedule II controlled substance under federal law. Food and Drug Administration (FDA) officials determined last year that the drug formulation is safe and effective for use by patients with cancer and AIDS. Two other synthetic Read the full article…

Federal Reclassification Of Marijuana Could Have Major Impact On Medical Uses

The DEA along with the U.S. Department of Health and Human Services and Office of National Drug Control Policy announced they would review marijuana's classification after multiple letters from senators last year, including Sen. Elizabeth Warren, D-Massachusetts, and Sen. Kirsten Gillibrand, D-New York.l

DISTRICT OF COLUMBIA: Federal authorities have announced that they are reviewing the possibility of loosening the classification of marijuana, and if this happens, it could have a far-reaching impact on how the substance is used in medical settings, experts said. Marijuana is currently classified as a Schedule I drug, meaning it is listed alongside heroin Read the full article…

DEA Eases Requirements For FDA-Approved Clinical Trials On Cannabidiol

These modifications will streamline the research process regarding CBD’s possible medicinal value and help foster ongoing scientific studies.

WASHINGTON: The United States Drug Enforcement Administration (DEA) recently eased some of the regulatory requirements imposed by the Controlled Substances Act (CSA) for those who are conducting FDA-approved clinical trials on cannabidiol (CBD), an extract of the marijuana plant.  These modifications will streamline the research process regarding CBD’s possible medicinal value and help foster ongoing scientific studies. Read the full article…

Did GW Pharmaceuticals (GWPH) Just Destroy The CBD-Product Industry?

The Food and Drug Administration (FDA) announced that products which contain cannabidiol (CBD) cannot be sold as dietary supplements.

DISTRICT OF COLUMBIA:  The Food and Drug Administration (FDA) announced that products which contain cannabidiol (CBD) cannot be sold as dietary supplements. The agency, however, left open the possibility that would it consider contrary evidence. The FDA’s website provides questions and answers pertaining its policies on marijuana. The way the questions were written provides avenues Read the full article…

Medical Marijuana Just Scored A Huge Victory At A San Francisco Hospital

San Francisco General Hospital is making strides in developing a marijuana-derived treatment for sickle-cell anemia.

CALIFORNIA:  San Francisco General Hospital is making strides in developing a marijuana-derived treatmentfor sickle-cell anemia, a blood disorder that affects over millions worldwide, including 10% of African Americans in the U.S. It causes severe pain throughout the body. The condition is currently treated using opiate painkillers, but researchers believe that CBD, one of the compounds in marijuana, could Read the full article…